Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „setting“
Suchtreffer
Begriffe & Kennungen
RoActemra · 4.8 · Skin reactions Rare reports of Stevens-Johnson Syndrome have occurred in the post-marketing setting.
Eintrag öffnenRoActemra · 4.8 · Very rare reports of pancytopenia have occurred in the post-marketing setting.
Eintrag öffnenRoActemra · 4.8 · Very rare reports of pancytopenia have occurred in the post-marketing setting.
Eintrag öffnenRoActemra · 4.8 · Very rare reports of pancytopenia have occurred in the post-marketing setting.
Eintrag öffnenSarclisa · 4.8 · The adverse reactions were reported in clinical studies (see section 5.1) and post-market settings.
Eintrag öffnenSarclisa · 4.8 · The adverse reactions were reported in clinical studies (see section 5.1) and post-market settings.
Eintrag öffnenSetting-sun eye phenomenon
Eintrag öffnenSoliris · 4.8 · Cases of haemolysis have been reported in the setting of missed or delayed Soliris dose in PNH clinical trials
Eintrag öffnenSoliris · 4.8 · Cases of thrombotic microangiopathy complication have been reported in the setting of missed or delayed Soliri
Eintrag öffnenSpinraza · 4.8 · Events of communicating hydrocephalus have been observed in the post-marketing setting (see section 4.4).
Eintrag öffnenStoboclo · 4.8 · Drug-related hypersensitivity reactions In the post-marketing setting, rare events of drug-related hypersensit
Eintrag öffnenStoboclo · 4.8 · In the post-marketing setting, rare cases of severe symptomatic hypocalcaemia resulting in hospitalisation, li
Eintrag öffnenTecentriq · 4.8 · 84 Use of atezolizumab in the adjuvant NSCLC setting
Eintrag öffnenTecentriq · 4.8 · The safety profile of atezolizumab in the adjuvant setting in the non-small cell lung cancer (NSCLC) patient p
Eintrag öffnenTecentriq · 4.8 · The safety profile of atezolizumab in the adjuvant setting in the non-small cell lung cancer (NSCLC) patient p
Eintrag öffnenTecentriq · 4.8 · Use of atezolizumab in the adjuvant NSCLC setting
Eintrag öffnenTevagrastim · 4.8 · In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disea
Eintrag öffnenThyrogen · 4.8 · Manifestations of hypersensitivity have been reported uncommonly in both clinical and post-marketing settings.
Eintrag öffnenTorisel · 4.8 · Table 2: Adverse reactions reported in post-marketing setting
Eintrag öffnenTrisenox · 4.8 · Mortality in the pivotal studies in the relapsed setting from disseminated intravascular coagulation (DIC) ass
Eintrag öffnen